Hidradenitis suppurativa and adalimumab in the COVID-19 era

Eur J Dermatol. 2020 Dec 1;30(6):748-749. doi: 10.1684/ejd.2020.3927.
No abstract available

Publication types

  • Case Reports
  • Multicenter Study

MeSH terms

  • Adalimumab / therapeutic use*
  • Adult
  • Aged
  • COVID-19 / complications*
  • COVID-19 / epidemiology*
  • Female
  • Hidradenitis Suppurativa / complications*
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Risk Assessment

Substances

  • Adalimumab